 | | Anno I – Numero 2 | Comitato scientifico editoriale: Orazio Caffo, Marcello Tucci
Editore: Intermedia, Direttore Responsabile: Mauro Boldrini | | | | Pubblicazioni recenti |
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives the growth of prostate cancer cells, and poly(ADP-ribose) polymerase. This association provides a rationale for their co-inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC), an area of unmet medical need. The phase 3 TALAPRO-2 study investigated combining the poly(ADP-ribose) polymerase inhibitor talazoparib with … Continua a leggere
| Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial
Purpose: Phase III PROfound trial (ClinicalTrials.gov identifier: NCT02987543) met its primary and key secondary objectives, demonstrating significantly longer radiographic progression-free survival (rPFS) and overall survival (OS) with olaparib monotherapy versus abiraterone or enzalutamide (control) in patients with metastatic castration-resistant prostate cancer (mCRPC) with alterations in BRCA1, BRCA2 (BRCA) … Continua a leggere
| Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
Background: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have a high risk of progression to metastatic disease, particularly if their prostate-specific antigen doubling time (PSADT) is ≤6 mo. However, patients remain at a high risk with a PSADT of >6 mo. Objective: To evaluate the efficacy and safety of darolutamide versus placebo in patients stratified by PSADT >6 or ≤6 mo. … Continua a leggere
| Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Background: The TheraP study reported improved prostate-specific antigen responses with lutetium-177 [177Lu]Lu-PSMA-617 versus cabazitaxel in men with metastatic castration-resistant prostate cancer progressing after docetaxel. In this Article, we report the secondary outcome of overall survival with mature follow-up, and an updated imaging biomarker analysis. We also report the outcomes of participants excluded due to ineligibility … Continua a leggere
| Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial
Objective: To assess, the effect of darolutamide (a structurally distinct androgen receptor inhibitor) on urinary and bowel symptoms, using data from the phase III ARAMIS trial (NCT02200614) that showed darolutamide significantly reduced the risk of metastasis and death versus placebo. Patients and methods: Patients with non-metastatic castration-resistant prostate cancer (nmCRPC) were randomised 2:1 to darolutamide (n = 955) or placebo (n = 554) … Continua a leggere
| | Videopillola |
#AIOM23 | Tumore della prostata: le Linee guida AIOM | Giuseppe Procopio
Clicca qui per vedere la videointervista
| | Appuntamenti |
Making Palliative Care a part of your Oncology Practice
I mercoledì dell’oncologia
Webinar, 10 gennaio 2024 dalle 17.00 alle 18.15
Corso per Quality Assurance e Auditor
FAD, 11 gennaio – 18 marzo 2024
Back from San Antonio 2024
Genova, 12 – 13 gennaio 2024
Quali le sfide da affrontare nel Tumore Germinale del testicolo
I mercoledì dell’oncologia
Webinar, 17 gennaio 2024 dalle 17.00 alle 18.15
Best from San Antonio 2023
Webinar ECM, 25 gennaio 2024
La Ricerca alla Portata del Paziente 3.0
Roma, 26 gennaio 2024
SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2024
Negrar (VR), 26 – 27 gennaio 2024
Questi e altri appuntamenti si possono consultare sul sito AIOM: www.aiom.it
|
© 2023 Editore: Intermedia srl Via Lunga 16a Brescia, BS 25124 Italy
tel. 030 226105 – 3888896214 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Iscrizione al Registro degli Operatori di Comunicazione N. 4867
Per contattare la redazione e commentare le notizie clicca qui
Ricevi questa email perché sei iscritto alla newsletter AIOM Cancellati
Privacy
Realizzata con il contributo non condizionante di Bayer
|
|
|
|
|